Correction to: PrevAleNce and Associated factors of inappropriaTe dosing of direct Oral anticoaguLants In pAtients with Atrial Fibrillation: the ANATOLIA-AF Study (Cardiovascular Drugs and Therapy, (2024), 38, 3, (581-599), 10.1007/s10557-022-07409-w)

In the following article published in Cardiovascular Drugs and Therapy, December 17, 2022, the subtitle of Table 1 included an incorrect phrase: “For patients receiving rivaroxaban or for patients receiving apixaban or for patients receiving edoxaban.” (Table presented.) Criteria for defining a patient as requiring a reduced dose of direct oral anticoagulants in the ANATOLIA-AF study For patients receiving dabigatran • Age ≥ 80 years • Concomitant usage of verapamil • ≥ 2 of the following criteria: age 75–79 years, GFR 30–50 mL/min/1.73 m2, HAS-BLED score ≥ 3, concomitant usage of antiplatelet therapy, concomitant usage of amiodarone, or body weight ≤ 60 kg For patients receiving rivaroxaban • GFR 15–49 mL/min/1.73 m2 • ≥ 2 of the following criteria: age ≥ 75 years, HAS-BLED score ≥ 3, concomitant usage of antiplatelet therapy, concomitant usage of amiodarone, or body weight ≤ 60 kg For patients receiving apixaban • ≥ 2 of the following criteria: age ≥ 80 years, serum creatinine ≥ 1.5 mg/dL, or body weight ≤ 60 kg • GFR 15–29 mL/min/1.73 m2 • ≥ 2 of the following criteria: age ≥ 75 years, HAS-BLED score ≥ 3, concomitant usage of antiplatelet therapy, concomitant usage of amiodarone, or concomitant usage of diltiazem For patients receiving edoxaban • GFR 15–49 mL/min/1.73 m2 • Body weight ≤ 60 kg • Concomitant usage of strong P-glycoprotein inhibitor (e.g., dronedarone, ketoconazole, erythromycin) • ≥ 2 of the following criteria: age ≥ 75 years, HAS-BLED score ≥ 3, concomitant usage of antiplatelet therapy, concomitant usage of amiodarone, or concomitant usage of verapamil GFR glomerular filtration rate, HAS-BLED uncontrolled hypertension, abnormal renal and liver function (1 point each), stroke, bleeding, labile international normalized ratios, elderly (age > 65 years), drugs or alcohol (1 point each) (concomitant use of antiplatelet agents or non-steroidal anti-inflammatory drugs, alcohol abuse). This has been deleted and replaced with the correction subheading “For patients receiving dabigatran.” Below is Table 1 including this correction. © Springer Science+Business Media, LLC, part of Springer Nature 2023.